Labiotech.eu’s Post

 💰 𝐂𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭𝐢𝐯𝐞 𝐁𝐢𝐨 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 £𝟒𝟑𝐌 𝐢𝐧 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐆𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐆𝐞𝐧𝐨𝐦𝐞 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 💰 Constructive Bio, a synthetic genomics startup, has raised $75 million in total through the first close of its Series A fundraising, which brought in an additional £43 million. The round was led by Ahren, OMX Ventures, and Paladin Capital Group, with additional participation from Fine Structure Ventures, +ND Capital, and Jonathan Milner, founder of Abcam. Constructive Bio's cutting edge technology , which enables the company to write entire genomes from scratch and construct an entirely new biomolecule, will be developed faster thanks to the additional cash. The company aims to revolutionize industries ranging from pharmaceuticals to materials and consumer goods with its novel biomanufacturing capabilities  As part of the investment, Sir Gregory Winter, a biotechnologist who won the Nobel Prize, will will join the board of Constructive Bio, representing Ahren. It is anticipated that Sir Gregory would contribute his wealth of knowledge to assist the business in growing its technological and business applications. Ola (Aleksandra) Wlodek, CEO of Constructive Bio, said the funding will enable the company to bring breakthrough products and platforms to market, driving revenue growth through new and existing pathways.“Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionise drug manufacturing and discovery.” The company, founded by Professor Jason Chin, operates on proprietary technology developed at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge. Constructive Bio is the first to create a fully synthetic strain of E.coli and is now advancing its platform to engineer protein translation and create entirely new molecules. Constructive Bio’s capacity to produce fully programmable molecules is expected to accelerate drug development and improve biomanufacturing scalability. Its proprietary platforms are being deployed across a range of sectors, including pharmaceuticals, chemicals, and sustainable materials.  Professor Jason Chin, CSO, added: “Constructive Bio is the only company that can turn living cells into sustainable biofactories in which we can programme the sequence, composition and chemistry of proteins, and new biopolymers, With additional funding we are accelerating genome synthesis and design from years to days, more rapidly engineering cells’ machinery to make molecules with extra building blocks, and expanding the chemistry we can programme into molecules.” Source: https://lnkd.in/eMkTMf-4 Reach out for early access to #SyntheticBiology #KnowledgeHub

Which city is ranked #1 for Biopharma in 2024? Article in Genetic Engineering & Biotechnology News discusses the research and reveals the rankings. What did these regions do right? According to the researchers, the top three regions: 1. Invested in biotech early “At the regional level,” the commentary noted, “pioneering has a long and lasting impact. Analysis reveals that the impact of early investments in an emerging field such as biotech spans more than three decades.” 2. Generated science of outstanding quantity and quality Scientific excellence was sustained even as the industry matured. 3. Built networks with partners These networks included organizations and individuals outside of the region. Broadened their clusters beyond anchor businesses. Each region included organizations besides a single multinational giant. The 2024 rankings criteria included: Talent Pool:  The concentration of skilled professionals, supported by leading universities and research institutions, is paramount. A robust educational infrastructure ensures a continuous influx of fresh talent and innovative thinking. Research Funding:  Access to substantial public and private research funding fuels groundbreaking discoveries. Strong financial support from government grants, venture capital, and private investments propels research and development efforts. Industry Presence:  A high density of biopharma companies, ranging from startups to established giants, fosters a collaborative and competitive environment. This ecosystem promotes innovation and accelerates the commercialization of new therapies. Infrastructure:  State-of-the-art facilities, advanced laboratory spaces, and supportive regulatory environments are critical for research and production activities. These physical and regulatory infrastructures enable efficient and effective biotech operations. Collaborations and Partnerships:  Proximity to hospitals, academic institutions, and other biotech companies enhances opportunities for partnerships and collaborative research projects. These alliances are crucial for translating research into real-world medical solutions. Quality of Life:  Attractive living conditions, including affordable housing, cultural amenities, and a vibrant community, help attract and retain top talent in the region. Click below to see where your city ranked. https://lnkd.in/gBpVdfxc #biotech #rankings #biopharma #NIHfunding #innovation #venturecapital

🇫🇷 (1/2) France is Investing in Biotech Innovation: Last week, I attended Viva Technology 2024 and discovered that France represented more biotech-based startups than any other country. Let’s dive into the CNRS - Centre national de la recherche scientifique (CNRS) stand, one of the biggest scientific institutions in French research: Biomemory TECH: DNA-based data storage. Their innovative approach leverages the long-term stability and high density of DNA to store vast amounts of data. The process is sustainable, significantly reducing carbon emissions compared to traditional data storage methods such as magnetic tapes. BUSINESS: In 2022, they raised €5M in a seed round, attracting several big investors. Their aim is to commercialize their DNA data storage solutions by focusing on reducing costs and improving technology scalability. By optimizing their product, they expect to have a cost-competitive solution with traditional storage methods within the next few years. Vect-Horus TECH: Peptide-based vectors for drug delivery across the blood-brain barrier (BBB). Their technology enables more effective delivery of therapeutic agents to targeted tissues, enhancing the efficacy and safety of treatments. BUSINESS: The company's plan focuses on advancing their drug delivery technology through preclinical and clinical stages. They have already licensed one of their technologies to Novo Nordisk but still have candidates to pursue with in-house development. France seems to be committed to biotech innovation, and I am excited to see how these startups will shape the future of healthcare and technology. Let's continue to deepen on the event and the other proposals from the CNRS tomorrow. #Biotech #Innovation #France #VivaTech2024 #CNRS #DNADataStorage #Startups #TechTrends #ScienceAndTechnology #ResearchAndDevelopment #BiotechStartups

In the age of transformative biotechnology, biofoundries are emerging as game-changers for India’s life sciences ecosystem. These advanced facilities integrate automation, high-throughput experimentation, and data analytics to accelerate the design and production of biological systems. Bio-innovation and bio-manufacturing are the two key drivers promoting India’s bioeconomy, and biofoundries offer access to both. This creates unique opportunities for emerging startups to use innovative resources, streamline development processes, and reduce costs, positioning them for growth and global competitiveness. BioAngels believes a network of biofoundries across India could foster innovation at an unprecedented scale, enabling startups to push boundaries in fields like synthetic biology, pharmaceuticals, and environmental biotechnology. Such a network would not only enhance resource-sharing and collaboration but also strengthen India’s value creation pipeline in biosciences, ultimately driving impactful solutions to pressing health and environmental challenges. Read more: https://lnkd.in/daxRGtAw #BioAngels #Biofoundries #BiotechInnovation #LifeSciences #SupportingStartups

🚀DEALFLASH - WEEK 42🚀 An overview of early-stage deals in European bio-, health- and life sciences. pre-seed. 🧫Corium Biotech Scope: Corium Biotech ™ is a brand by Maia & Muller – Biotech which manufactures exotic leather using cellular agriculture technologies. Investors: biotope by VIB, Portugal Ventures Ticket size: EUR 500k seed. 👁️Siloton Scope: Siloton is a medical device manufacturing company that designs and develops diagnostic imaging devices in the field of ophthalmology. Investors: Evenlode Foundation, South East Angels, The Francis Crick Institute Ticket size: GBP 860k 📈SOMAREALITY Scope: Spatial Computing, Eye Tracking, Cognitive Digital Biomarkers Investors: n/a Ticket size: EUR 2.6 MM 🔬Antiverse Scope: Antiverse is dedicated to engineering the future of drug development to change the course of people's lives. Investors: AngelHub, Future Planet Capital, i&i Biotech Fund, Innospark Ventures, Kadmos Capital Ltd, Tensor Ventures, UK Innovation & Science Seed Fund Ticket size: GBP 3.5 MM 🧪Aerleum Scope: Aerleum Develops a groundbreaking system that combines CO2 capture and conversion to produce clean fuels and chemicals. Investors: 360 Capital, Bpifrance, HTGF | High-Tech Gründerfonds, Marble, Norrsken VC Ticket size: EUR 5.5 MM ⚙️Shift Bioscience Scope: Simulation guided target discovery for age-linked diseases Investors: BGF, F-Prime Capital, Kindred Capital VC, Meltwind Advisory LLP & angel investors Ticket size: GBP 12.5 MM series a. 🍴UMAMI Scope: Umami is a bionic farming company specialized in growing pure food with superior flavour. Investors: n/a Ticket size: CHF 4.3 MM 👨⚕️Minze Health Scope: Minze Health is a health tech start-up that builds digital health solutions for urology and pelvic health. Investors: Capricorn Partners, imec.istart future fund, PMV, White Fund SA Ticket size: USD 5.3 MM 💊invIOs INNOVATIVE IMMUNO-ONCOLOGY Scope: invIOs is a private biotech company that specializes in the discovery and development of next-generation cancer therapies. Investors: Ligand Pharmaceuticals Ticket size: EUR 8.2 MM other. 📊Kaminari Medical Scope: Kaminari Medical combines ultrasound and optical imaging to revolutionise coronary revascularisation Investors: Demcon, Graduate Entrepreneur Fund, Libertatis Ergo Holding B.V., NLC Health Ventures Ticket size: EUR 2.3 MM Looking for easier and more successful fundraising in bio-, health- and life sciences? Contact us at hello@ensemblate.com. #innovation #lifesciences #fundraising #venturecapital

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet DoriNano! Q: Tell us about your company and what you’re developing. What are you most excited about? A: DoriNano, a Harvard spinoff, pioneers the use of DNA origami nanoparticles as a transformative delivery platform for combination immunotherapies, offering precise cellular targeting and minimal effective doses of cargo for treating serious diseases. Our mission is to develop safe, effective, and affordable combination nanomedicines that overcome past limitations in nanoparticle-based therapeutics. We are particularly excited about the multifaceted potential of DNA origami nanoparticles, which have the potential to revolutionize the nanotechnology delivery landscape. Q: What advice do you have for other biotech companies just getting started? A: Starting a biotech company requires resilience, a willingness to learn, and openness to suggestions. Every challenge presents an opportunity for growth. Embrace the journey, endure sacrifice, minimize complaints, learn from setbacks, and move forward. Building the right team is the key and most challenging sector. Surround yourself with dedicated individuals who share your vision.  Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The MassBioDrive program's structured approach, coupled with the dedication of organizers and mentors, has been very impactful. The informative working sessions cover vital aspects of company launch, regulatory compliance, legal considerations, CMC considerations, investment strategies and pharma partnering. As a scientist-turned-entrepreneur, these resources have been invaluable, providing comprehensive guidance tailored to our needs. The interactive Q&A sessions during both mentor sessions and working sessions have deepened our comprehension and helped address questions regarding the company’s development. Learn more about DoriNano: https://lnkd.in/eXJ7PQ_X Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b Yang (Claire) Zeng

Incheon Free Economic Zone and SparkLabs to launch 'Bio Open Lab' in Songdo International Business District - Attracting KRW 500 billion in private investment: MOU signed for 'F3-3 Block' project development in Songdo International Business District - Supporting startups in the biotechnology sector with global accelerator ‘SparkLabs’ at the core - Open lab space offering bio data, shared laboratories, and youth housing for incoming companies https://lnkd.in/g3yFuh8C

#CMI0324: #Chemistry & Life Sciences Europe’s Biotech Cluster Powerhouses: Knowledge, Innovation, Financing: What makes a successful #biotech region Whether Cambridge, Leiden, Heidelberg or Paris — many European countries have #biotechnology clusters in which scientific expertise meets a well-developed infrastructure, committed entrepreneurship and attractive financing opportunities. The drugs of tomorrow often emerge from such knowledge conglomerates. But what characterizes the outstanding biotech hubs on the European continent? A subjective look at the best. The discussion on the online platform Reddit, Inc. is symptomatic for the structure of the biotech industry. A user from the USA asks which are the most important biotech hubs in Europe. The feedback overwhelms him: “Seems like the Europeans are giving a ton of different answers. Would you guys say the biotech industry is just distributed more evenly across the continent compared to the US? It seems very different compared to here.” In fact, while Europe has numerous biotech hubs, only one or at most two centers stand out in the USA: Boston/Cambridge and the San Francisco Bay Area. Network, Funding, Patents, Jobs: But what characterizes a successful, strong #cluster? US Commercial real estate investor Brad Thomas says: “There is a unique desire among life science entities to cluster together in campus ecosystems in order to drive productivity and collaboration, to recruit and retain top talent, to attract strategic capital, and to ensure best-in-class, 24/7 operations of their mission-critical real estate.” Ralf Huss, Managing Director of the Bavarian BioM Biotech Cluster Development GmbH company, goes into more detail: “The outstanding thing (...) is a network based on excellent science and also partly applied research (at least in selected key areas), efficient technology transfer in translation centers with the possibilities of accelerated #incubation, a sustainable industrial environment consisting of start-ups, successful SMEs and, if possible, globally active #pharmaceutical and biotech companies. In addition, there is a supportive policy at local, regional and national level with a close relationship to European decision-makers. Such a cluster is a strong partner for global and strategic investors, which is an important driver for further growth.” (...) For its part, the Boston Consulting Group (BCG), together with the DEEP - Institute for Deep Tech Innovation and the Berlin educational institution ESMT Berlin, designed a so-called Biotech Innovation Hub Index (BIHI) to help evaluate and compare the effectiveness of biotech innovation hubs. (...) Read the full overview from CHEManager author Thorsten Schüller in the latest #CMI issue: https://lnkd.in/evXdqQYy

ZipBio, a New Seattle Biotech Startup Aiming to Compress Proteins, Raises $4M https://lnkd.in/gWdSUDsj Seattle-based biotech startup ZipBio announced its official launch and revealed $4 million in a seed funding round led by NFX. ZipBio, founded in 2023, is developing a platform that “compresses complex biological structures into smaller, more efficient de novo-designed proteins that retain full functionality, optimizing delivery and therapeutic effectiveness,” according to the company. The company uses generative AI to transform the development of new therapeutics that address some of the most critical unmet needs in healthcare. By creating de novo genes and proteins, ZipBio distills multiple complex functions into compact highly effective therapeutic molecules. The post ZipBio, a New Seattle Biotech Startup Aiming to Compress Proteins, Raises $4M appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

The Future of LA Biotech: Nirdosh Jagota's Insights on Innovations 🔬🌟 Nirdosh Jagota is in charge of Los Angeles' biotech landscape, where innovation meets opportunity. With a keen eye on emerging technologies and groundbreaking research, Jagota explores how advancements in biotechnology are reshaping healthcare and improving patient outcomes. His insights emphasize the importance of collaboration among researchers, entrepreneurs, and investors to drive sustainable growth in the industry. By championing a culture of innovation and adaptability, Jagota is not only influencing the trajectory of LA's biotech scene but also inspiring the next wave of discoveries that could revolutionize the field. #Biotech #Innovation #Healthcare #NirdoshJagota #LAtech https://lnkd.in/eB8tcdw7